

Nick Peter Curzen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2227781/publications.pdf>

Version: 2024-02-01

139
papers

9,404
citations

109321

35
h-index

38395

95
g-index

140
all docs

140
docs citations

140
times ranked

8522
citing authors

#	ARTICLE	IF	CITATIONS
1	Fractional Flow Reserve—Guided PCI versus Medical Therapy in Stable Coronary Disease. New England Journal of Medicine, 2012, 367, 991-1001.	27.0	2,248
2	Fractional Flow Reserve—Guided PCI for Stable Coronary Artery Disease. New England Journal of Medicine, 2014, 371, 1208-1217.	27.0	905
3	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	2.8	807
4	Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease. Journal of the American College of Cardiology, 2015, 65, 963-972.	2.8	662
5	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
6	Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR _{CT} : outcome and resource impacts study. European Heart Journal, 2015, 36, 3359-3367.	2.2	467
7	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet, The, 2019, 394, 1325-1334.	13.7	406
8	1-Year Outcomes of FFRCT-Guided Care in Patients With Suspected Coronary Disease. Journal of the American College of Cardiology, 2016, 68, 435-445.	2.8	313
9	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 2015, 36, 100-111.	2.2	241
10	Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?. Circulation: Cardiovascular Interventions, 2014, 7, 248-255.	3.9	205
11	Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography. Journal of the American College of Cardiology, 2015, 66, 2315-2323.	2.8	164
12	A Prospective Natural History Study of Coronary Atherosclerosis Using Fractional Flow Reserve. Journal of the American College of Cardiology, 2016, 68, 2247-2255.	2.8	118
13	Percutaneous coronary intervention in the UK: recommendations for good practice 2015. Heart, 2015, 101, 1-13.	2.9	91
14	Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 56.	7.4	88
15	Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart, 2020, 106, 1805-1811.	2.9	87
16	International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. Journal of the American College of Cardiology, 2021, 77, 2466-2476.	2.8	78
17	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. European Heart Journal, 2021, 42, 3844-3852.	2.2	74
18	Changes in Arterial Access Site and Association With Mortality in the United Kingdom. Circulation, 2016, 133, 1655-1667.	1.6	71

#	ARTICLE	IF	CITATIONS
19	Outcomes in Patients With Cardiogenic Shock Following Percutaneous Coronary Intervention in the Contemporary Era. JACC: Cardiovascular Interventions, 2014, 7, 1374-1385.	2.9	70
20	Intravascular Imaging and 12-Month Mortality After Unprotected Left Main Stem-PCI. JACC: Cardiovascular Interventions, 2020, 13, 346-357.	2.9	70
21	Meta-Analysis of the Prognostic Impact of Anemia in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 610-620.	1.6	58
22	A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets, 2007, 18, 497-505.	2.3	55
23	Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. British Journal of Clinical Pharmacology, 2011, 72, 683-696.	2.4	54
24	Impact of COVID-19 on cardiac procedure activity in England and associated 30-day mortality. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 247-256.	4.0	54
25	Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart, 2018, 104, 1683-1690.	2.9	50
26	Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost. JACC: Cardiovascular Interventions, 2018, 11, 665-674.	2.9	49
27	Complete Versus Lesion-Only Primary PCI. Journal of the American College of Cardiology, 2015, 66, 2713-2724.	2.8	43
28	Health Economic Analysis of Access Site Practice in England During Changes in Practice. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004482.	2.2	43
29	Outcomes of COVID-19-positive acute coronary syndrome patients: A multisource electronic healthcare records study from England. Journal of Internal Medicine, 2021, 290, 88-100.	6.0	43
30	Simulation of longitudinal stent deformation in a patient-specific coronary artery. Medical Engineering and Physics, 2014, 36, 467-476.	1.7	41
31	Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis. BMC Cardiovascular Disorders, 2016, 16, 177.	1.7	41
32	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation, 2021, 144, 96-109.	1.6	41
33	True 99th centile of high sensitivity cardiac troponin for hospital patients: prospective, observational cohort study. BMJ: British Medical Journal, 2019, 364, l729.	2.3	40
34	Baseline risk, timing of invasive strategy and guideline compliance in NSTEMI: Nationwide analysis from MINAP. International Journal of Cardiology, 2020, 301, 7-13.	1.7	40
35	Impact of the COVID-19 Pandemic on Percutaneous Coronary Intervention in England. Circulation: Cardiovascular Interventions, 2020, 13, e009654.	3.9	39
36	Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMI and Multivessel Disease. Journal of the American College of Cardiology, 2019, 74, 3083-3094.	2.8	38

#	ARTICLE	IF	CITATIONS
37	Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. <i>Heart</i> , 2011, 97, 1661-1667.	2.9	33
38	Increased Radial Access Is Not Associated With Worse Femoral Outcomes for Percutaneous Coronary Intervention in the United Kingdom. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, e004279.	3.9	33
39	Same-Day Discharge After Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1479-1494.	2.9	33
40	Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, 3148-3161.	2.2	32
41	The impact of imperfect frame deployment and rotational orientation on stress within the prosthetic leaflets during transcatheter aortic valve implantation. <i>Journal of Biomechanics</i> , 2017, 53, 22-28.	2.1	30
42	â€œShortâ€thrombelastography as a test of platelet reactivity in response to antiplatelet therapy: Validation and reproducibility. <i>Platelets</i> , 2011, 22, 210-216.	2.3	27
43	Racial differences in management and outcomes of acute myocardial infarction during COVID-19 pandemic. <i>Heart</i> , 2021, 107, 734-740.	2.9	27
44	Relation of Frailty to Outcomes in Percutaneous Coronary Intervention. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 811-818.	0.8	26
45	â€Valve for Lifeâ€™: tackling the deficit in transcatheter treatment of heart valve disease in the UK. <i>Open Heart</i> , 2021, 8, e001547.	2.3	26
46	Sensitivity and specificity of the subcutaneous implantable cardioverter defibrillator pre-implant screening tool. <i>International Journal of Cardiology</i> , 2015, 195, 205-209.	1.7	25
47	Physiology-Guided Management of Serial Coronary Artery Disease. <i>JAMA Cardiology</i> , 2018, 3, 432.	6.1	24
48	Operator volume is not associated with mortality following percutaneous coronary intervention: insights from the British Cardiovascular Intervention Society registry. <i>European Heart Journal</i> , 2018, 39, 1623-1634.	2.2	24
49	Is There a Relationship of Operator and Center Volume With Access Siteâ€Related Outcomes?. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003333.	3.9	23
50	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. <i>European Heart Journal</i> , 2021, 43, 56-67.	2.2	23
51	The relationship between the contralateral collateral supply and myocardial viability on cardiovascular magnetic resonance: Can the angiogram predict functional recovery?. <i>International Journal of Cardiology</i> , 2014, 177, 362-367.	1.7	21
52	Safety of guidewire-based measurement of fractional flow reserve and the index of microvascular resistance using intravenous adenosine in patients with acute or recent myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 305-310.	1.7	20
53	Temporal Trends in Identification, Management, and Clinical Outcomes After Out-of-Hospital Cardiac Arrest. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005346.	3.9	20
54	Outcomes Following Percutaneous Coronary Intervention in Nonâ€ST-Segmentâ€Elevation Myocardial Infarction Patients With Coronary Artery Bypass Grafts. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006824.	3.9	19

#	ARTICLE	IF	CITATIONS
55	Outcomes Following Percutaneous Coronary Intervention in Saphenous Vein Grafts With and Without Embolic Protection Devices. JACC: Cardiovascular Interventions, 2019, 12, 2286-2295.	2.9	19
56	Indirect Impact of the COVID-19 Pandemic on Activity and Outcomes of Transcatheter and Surgical Treatment of Aortic Stenosis in England. Circulation: Cardiovascular Interventions, 2021, 14, e010413.	3.9	19
57	Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention. Value in Health, 2017, 20, 745-751.	0.3	15
58	Association Between Hospital Cardiac Catheter Laboratory Status, Use of an Invasive Strategy, and Outcomes After NSTEMI. Canadian Journal of Cardiology, 2020, 36, 868-877.	1.7	15
59	Does the VerifyNow P2Y12 assay overestimate the therapeutic response to clopidogrel?. Thrombosis and Haemostasis, 2014, 111, 1150-1159.	3.4	14
60	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. Cost Effectiveness and Resource Allocation, 2015, 13, 19.	1.5	14
61	Coronary Artery Rupture Caused by Stent Infection. Circulation, 2015, 131, 1302-1303.	1.6	13
62	Multi-objective optimisation of stent dilation strategy in a patient-specific coronary artery via computational and surrogate modelling. Journal of Biomechanics, 2016, 49, 205-215.	2.1	13
63	Design and Rationale of the RIPCORDER 2 Trial (Does Routine Pressure Wire Assessment Influence) Tj ETQq1 1 0.784314 rgBT /Overlock Cardiovascular Quality and Outcomes, 2018, 11, e004191.	2.2	13
64	Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain: Rationale and Design of the FORECAST Trial. Cardiovascular Revascularization Medicine, 2020, 21, 890-896.	0.8	13
65	Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s. Cardiovascular Therapeutics, 2018, 36, e12433.	2.5	12
66	High sensitivity troponin in the management of tachyarrhythmias. Cardiovascular Revascularization Medicine, 2018, 19, 487-492.	0.8	12
67	Coronary perforation complicating percutaneous coronary intervention in patients presenting with an acute coronary syndrome: An analysis of 1013 perforation cases from the British Cardiovascular Intervention Society database. International Journal of Cardiology, 2020, 299, 37-42.	1.7	12
68	Is arachidonic acid stimulation really a test for the response to aspirin? Time to think again?. Expert Review of Cardiovascular Therapy, 2017, 15, 35-46.	1.5	11
69	Relative survival and excess mortality following primary percutaneous coronary intervention for ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 68-77.	1.0	11
70	Changes in platelet function with inflammation in patients undergoing vascular surgery. Platelets, 2019, 30, 190-198.	2.3	11
71	Uncovering the treatable burden of severe aortic stenosis in the UK. Open Heart, 2022, 9, e001783.	2.3	11
72	Should ischemia be the main target in selecting a percutaneous coronary intervention strategy?. Expert Review of Cardiovascular Therapy, 2013, 11, 1051-1059.	1.5	10

#	ARTICLE	IF	CITATIONS
73	Aspirin Resistance in Ischemic Stroke: Insights Using Short Thrombelastography. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 1412-1419.	1.6	10
74	Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography. Platelets, 2015, 26, 689-692.	2.3	10
75	Troponin assays: developing indications. Lancet, The, 2018, 391, 2398-2399.	13.7	10
76	Temporal trends and predictors of time to coronary angiography following non-ST-elevation acute coronary syndrome in the USA. Coronary Artery Disease, 2019, 30, 159-170.	0.7	10
77	High sensitivity troponin measurement in critical care: Flattering to deceive or "never means nothing"? Journal of the Intensive Care Society, 2020, 21, 232-240.	2.2	10
78	Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography. Case Reports in Medicine, 2016, 2016, 1-6.	0.7	9
79	Response by Piroth et al to Letter Regarding Article, "Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation": Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	9
80	Antiplatelet therapy in percutaneous coronary intervention: is variability of response clinically relevant?. Heart, 2011, 97, 1433-1440.	2.9	8
81	Change in angiogram-derived management strategy of patients with chest pain when some FFR data are available: How consistent is the effect?. Cardiovascular Revascularization Medicine, 2017, 18, 320-327.	0.8	8
82	High sensitivity troponins in contemporary cardiology practice: are we turning a corner?. Expert Review of Cardiovascular Therapy, 2018, 16, 49-57.	1.5	8
83	Temporal trends in relative survival following percutaneous coronary intervention. BMJ Open, 2019, 9, e024627.	1.9	8
84	Is the true clinical value of high-sensitivity troponins as a biomarker of risk? The concept that detection of high-sensitivity troponin "never means nothing". Expert Review of Cardiovascular Therapy, 2020, 18, 843-857.	1.5	8
85	A randomised controlled trial to compare two coronary pressure wires using simultaneous measurements in human coronary arteries: the COMET trial. EuroIntervention, 2019, 14, e1578-e1584.	3.2	8
86	Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel. Heart, 2012, 98, 1617-1619.	2.9	7
87	Clinical outcomes of percutaneous coronary intervention for chronic total occlusion in prior coronary artery bypass grafting patients. Catheterization and Cardiovascular Interventions, 2022, 99, 74-84.	1.7	7
88	Outcomes following PCI in CABG candidates during the COVID-19 pandemic: The prospective multicentre UK ReVasc registry. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	7
89	Impact of availability of catheter laboratory facilities on management and outcomes of acute myocardial infarction presenting with out of hospital cardiac arrest. Resuscitation, 2022, 170, 327-334.	3.0	7
90	Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial. Heart, 2021, 107, 299-312.	2.9	6

#	ARTICLE	IF	CITATIONS
91	Distribution of High-Sensitivity Troponin Taken Without Conventional Clinical Indications in Critical Care Patients and Its Association With Mortality*. Critical Care Medicine, 2021, 49, 1451-1459.	0.9	6
92	Coronary Physiology Derived from Invasive Angiography: Will it be a Game Changer?. Interventional Cardiology Review, 2020, 15, e06.	1.6	6
93	Changes in Periprocedural Bleeding Complications Following Percutaneous Coronary Intervention in The United Kingdom Between 2006 and 2013 (from the British Cardiovascular Interventional Society). American Journal of Cardiology, 2018, 122, 952-960.	1.6	5
94	One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008855.	3.9	5
95	Investigating the material modelling of a polymeric bioresorbable scaffold via in-silico and in-vitro testing. Journal of the Mechanical Behavior of Biomedical Materials, 2021, 120, 104557.	3.1	5
96	Distribution of contemporary sensitivity troponin in the emergency department and relationship to 30-day mortality: The CHARIOT-ED substudy. Clinical Medicine, 2020, 20, 528-534.	1.9	5
97	Adoption of same day discharge following elective left main stem percutaneous coronary intervention. International Journal of Cardiology, 2020, 321, 38-47.	1.7	4
98	Contributors to the Growth of Same Day Discharge After Elective Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008458.	3.9	4
99	Relation of High-Sensitivity Troponin to 1 Year Mortality in 20,000 Consecutive Hospital Patients Undergoing a Blood Test for Any Reason. American Journal of Cardiology, 2021, 158, 124-131.	1.6	4
100	Comparison of the effects of P2Y12 receptor antagonists on platelet function and clinical outcomes in patients undergoing Primary PCI: A substudy of the HEAT-PPCI trial. EuroIntervention, 2018, 13, 1931-1938.	3.2	4
101	Variation in emergency percutaneous coronary intervention in ventilated patients in the UK: Insights from a national database. Cardiovascular Revascularization Medicine, 2017, 18, 250-254.	0.8	3
102	Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial. Thrombosis Research, 2018, 172, 36-43.	1.7	3
103	DNA Damage and Repair in Patients With Coronary Artery Disease: Correlation With Plaque Morphology Using Optical Coherence Tomography (DECODE Study). Cardiovascular Revascularization Medicine, 2019, 20, 812-818.	0.8	3
104	Early Oxidative Stress Response in Patients with Severe Aortic Stenosis Undergoing Transcatheter and Surgical Aortic Valve Replacement: A Transatlantic Study. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-8.	4.0	3
105	Use of troponins in clinical practice: Evidence against the use of troponins in clinical practice. Heart, 2020, 106, 251-252.	2.9	3
106	Incidence and 1-year outcome of periprocedural myocardial infarction following cardiac surgery: are the Universal Definition and Society for Cardiovascular Angiography and Intervention criteria fit for purpose?. European Journal of Cardio-thoracic Surgery, 2022, 62, .	1.4	3
107	Can Interventional Cardiologists Help Deliver the UK Mechanical Thrombectomy Interventional Programme for Patients with Acute Ischaemic Stroke? A Discussion Paper from the British Cardiovascular Interventional Society Stroke Thrombectomy Focus Group. Interventional Cardiology Review, 0, 17, .	1.6	3
108	Prolonged antiplatelet therapy after drug-eluting stents. Lancet, The, 2015, 385, 2332-2333.	13.7	2

#	ARTICLE	IF	CITATIONS
109	Effect of Location on Treatment and Outcomes of Cardiac Arrest Complicating Acute Myocardial Infarction in England & Wales. American Journal of Cardiology, 2021, 152, 1-10.	1.6	2
110	Effect of the Timing of Admission of Out of Hospital Cardiac Arrest Complicating Acute Myocardial Infarction on Management and Outcome. American Journal of Cardiology, 2021, 156, 1-8.	1.6	2
111	Twelve Months Dual Antiplatelet Therapy after Drug-eluting Stents â€“ Too Long, too Short or Just Right?. Interventional Cardiology Review, 2015, 10, 136.	1.6	2
112	Comparison of plaque distribution and wire-free functional assessment in patients with stable angina and non-ST elevation myocardial infarction: an optical coherence tomography and quantitative flow ratio study. Coronary Artery Disease, 2021, 32, 131-137.	0.7	2
113	'Valve for Life': tackling the deficit in transcatheter treatment of heart valve disease in the UK. Open Heart, 2021, 8, .	2.3	2
114	Magnetic retrieval of prosthetic heart valves for redo-TAVI. Medical Engineering and Physics, 2022, 101, 103761.	1.7	2
115	Joint British Societiesâ€™ guideline on management of cardiac arrest in the cardiac catheter laboratory. Heart, 2022, , heartjnl-2021-320588.	2.9	2
116	Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial. BMJ Open, 2022, 12, e055878.	1.9	2
117	Presentation cardiac troponin and early computed tomography coronary angiography in patients with suspected acute coronary syndrome: a pre-specified secondary analysis of the RAPID-CTCA trial. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 570-579.	1.0	2
118	Consent in cardiology: there may be trouble ahead?. Heart, 2005, 91, 977-980.	2.9	1
119	Novel treatment for critical aortic stenosis with severe aortic root calcification and coronary disease: Combined left internal thoracic artery graft to left anterior descending coronary artery and deployment of transcatheter aortic valve implantation valve under direct vision. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, e53-e54.	0.8	1
120	Hobsonâ€™s Choice. Circulation: Cardiovascular Interventions, 2018, 11, e006577.	3.9	1
121	Deoxyribonucleic Acid Repair Activity Is Associated with Healed Coronary Plaque Rupture by Optical Coherence Tomography. Journal of Cardiovascular Translational Research, 2019, 12, 608-610.	2.4	1
122	Rotational atherectomy and same day discharge: Safety and growth from a national perspective. Catheterization and Cardiovascular Interventions, 2020, 98, 678-688.	1.7	1
123	Fractional flow reserve derived from coronary computed tomography: where are we now and where are we heading?. Future Cardiology, 2021, 17, 723-741.	1.2	1
124	Outcomes Following Percutaneous Coronary Intervention in Renal Transplant Recipients: A Binational Collaborative Analysis. Mayo Clinic Proceedings, 2021, 96, 363-376.	3.0	1
125	Treatment of Non-Culprit Lesions in STEMI: An Incomplete Journey. Cardiovascular Revascularization Medicine, 2022, 39, 114-116.	0.8	1
126	Clinical outcomes of percutaneous coronary intervention for chronic total occlusion by treated segment length. Catheterization and Cardiovascular Interventions, 2021, , .	1.7	1

#	ARTICLE	IF	CITATIONS
127	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. American Heart Journal, 2022, 246, 32-43.	2.7	1
128	Atheroma or ischemia: which is more important for managing patients with stable chest pain?. Future Cardiology, 2022, 18, 417-429.	1.2	1
129	Variation in practice for out-of-hospital cardiac arrest treated with percutaneous coronary intervention in England and Wales. Catheterization and Cardiovascular Interventions, 0, , .	1.7	1
130	Detection of multiregional transient myocardial ischaemia using a novel 80-electrode body surface Delta map. International Journal of Cardiology, 2015, 181, 114-116.	1.7	0
131	Should doctors strike?. Lancet, The, 2016, 387, 531.	13.7	0
132	Does the evidence really suggest that we should completely revascularise bystander disease in patients with ST elevation myocardial infarction undergoing primary angioplasty? Why we still need more definitive trial data to change routine practice. Expert Review of Cardiovascular Therapy, 2017, 15, 75-81.	1.5	0
133	The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?. Cardiovascular Revascularization Medicine, 2018, 19, 452-456.	0.8	0
134	Fractional flow reserve use during elective coronary angiography among elderly patients in the US. IJC Heart and Vasculature, 2019, 22, 160-162.	1.1	0
135	Should We Interrupt Oral Anticoagulation Before Percutaneous Coronary Intervention? A National Survey of UK Interventional Cardiologists. Heart Lung and Circulation, 2022, 31, e5-e6.	0.4	0
136	Is There Still a Place for Revascularisation in the Management of Stable Coronary Artery Disease Following the ISCHEMIA Trial?. Heart International, 2020, 14, 13.	1.4	0
137	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. Efficacy and Mechanism Evaluation, 2020, 7, 1-86.	0.7	0
138	Defining Successful PCI. JACC: Cardiovascular Interventions, 2022, 15, 62-64.	2.9	0
139	Ischaemic heart disease: stable angina. Medicine, 2022, , .	0.4	0